Value of cardiac biomarkers in patients with acute pulmonary embolism

Background: Prognostic stratification of patients with PE is important in management and potentially improve clinical outcome. Cardiac biomarkers are used as an adjunct to clinical and echocardiographic risk stratification in a variety of circumstances, (Creatine-kinase-MB “CK-MB”) and cardiac tropo...

Full description

Bibliographic Details
Main Authors: Eman O. Arram, Amal Fathy, Ayman A. Abdelsamad, Emad I. Elmasry
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2014-01-01
Series:Egyptian Journal of Chest Disease and Tuberculosis
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0422763813002082
id doaj-e1f643c3c57f44aba7cf106b02ef564f
record_format Article
spelling doaj-e1f643c3c57f44aba7cf106b02ef564f2020-11-25T00:08:57ZengWolters Kluwer Medknow PublicationsEgyptian Journal of Chest Disease and Tuberculosis0422-76382014-01-0163124725210.1016/j.ejcdt.2013.09.016Value of cardiac biomarkers in patients with acute pulmonary embolismEman O. Arram0Amal Fathy1Ayman A. Abdelsamad2Emad I. Elmasry3Chest Department, Mansoura University, Mansoura, EgyptChest Department, Mansoura University, Mansoura, EgyptCardiology Department, Mansoura University, Mansoura, EgyptClinical Pathology Department, Mansoura University, Mansoura, EgyptBackground: Prognostic stratification of patients with PE is important in management and potentially improve clinical outcome. Cardiac biomarkers are used as an adjunct to clinical and echocardiographic risk stratification in a variety of circumstances, (Creatine-kinase-MB “CK-MB”) and cardiac troponin I (cTnI) are most widely used because of their high sensitivities, and very high specificity of troponin for heart muscle injury. Evidence is mounting that myoglobin’s sensitivity for myocardial necrosis combined with its unique release and clearance properties may render it particularly attractive as a risk marker either alone or in combination with other markers. Objectives: The aim of the current study is to assess the levels of cardiac specific biomarkers in relation to different clinical, ECG and echocardiogrphic findings in patients with acute PE, as well as evaluating the prognostic value of these biomarkers for inhospital mortality and adverse clinical events. Patients and methods: This study comprised 40 patients with proved PE (22 males and 18 females), their mean age was 50.05 ± 13.09 years (range 22–70 years). The following investigations were performed for all patients; 12-leads ECG, Full echo Doppler study, spiral CT of the chest, and laboratory testing: arterial blood gas, serum myoglobin, serum troponin, total CK and CK-MB, kidney and liver function tests. Result: Significant elevation of CK-MB (>10 μ/L) was noted only in 7.5% of patients, while cardiac cTnI was elevated (⩾0.07 ng/ml) in 45% of patients and elevated serum myoglobin was found very early after symptoms (<4 h) in 55% of patients. Elevated serum cTnI and myoglobin were significantly associated with ECG signs of right ventricular strain and echocardiographic evidence of right ventricular dysfunction. Conclusion: The results of the present study demonstrate the prognostic value of cardiac specific biomarkers, cardiac troponin I & myoglobin in acute pulmonary embolism. Thus, the current data combined with the results of previous studies strongly support the integration of troponin and myoglobin testing into the risk stratification and management of patients with established acute PE.http://www.sciencedirect.com/science/article/pii/S0422763813002082Pulmonary embolismCreatine-kinase-MBCardiac troponin IEchocardiographyCardiac biomarkers
collection DOAJ
language English
format Article
sources DOAJ
author Eman O. Arram
Amal Fathy
Ayman A. Abdelsamad
Emad I. Elmasry
spellingShingle Eman O. Arram
Amal Fathy
Ayman A. Abdelsamad
Emad I. Elmasry
Value of cardiac biomarkers in patients with acute pulmonary embolism
Egyptian Journal of Chest Disease and Tuberculosis
Pulmonary embolism
Creatine-kinase-MB
Cardiac troponin I
Echocardiography
Cardiac biomarkers
author_facet Eman O. Arram
Amal Fathy
Ayman A. Abdelsamad
Emad I. Elmasry
author_sort Eman O. Arram
title Value of cardiac biomarkers in patients with acute pulmonary embolism
title_short Value of cardiac biomarkers in patients with acute pulmonary embolism
title_full Value of cardiac biomarkers in patients with acute pulmonary embolism
title_fullStr Value of cardiac biomarkers in patients with acute pulmonary embolism
title_full_unstemmed Value of cardiac biomarkers in patients with acute pulmonary embolism
title_sort value of cardiac biomarkers in patients with acute pulmonary embolism
publisher Wolters Kluwer Medknow Publications
series Egyptian Journal of Chest Disease and Tuberculosis
issn 0422-7638
publishDate 2014-01-01
description Background: Prognostic stratification of patients with PE is important in management and potentially improve clinical outcome. Cardiac biomarkers are used as an adjunct to clinical and echocardiographic risk stratification in a variety of circumstances, (Creatine-kinase-MB “CK-MB”) and cardiac troponin I (cTnI) are most widely used because of their high sensitivities, and very high specificity of troponin for heart muscle injury. Evidence is mounting that myoglobin’s sensitivity for myocardial necrosis combined with its unique release and clearance properties may render it particularly attractive as a risk marker either alone or in combination with other markers. Objectives: The aim of the current study is to assess the levels of cardiac specific biomarkers in relation to different clinical, ECG and echocardiogrphic findings in patients with acute PE, as well as evaluating the prognostic value of these biomarkers for inhospital mortality and adverse clinical events. Patients and methods: This study comprised 40 patients with proved PE (22 males and 18 females), their mean age was 50.05 ± 13.09 years (range 22–70 years). The following investigations were performed for all patients; 12-leads ECG, Full echo Doppler study, spiral CT of the chest, and laboratory testing: arterial blood gas, serum myoglobin, serum troponin, total CK and CK-MB, kidney and liver function tests. Result: Significant elevation of CK-MB (>10 μ/L) was noted only in 7.5% of patients, while cardiac cTnI was elevated (⩾0.07 ng/ml) in 45% of patients and elevated serum myoglobin was found very early after symptoms (<4 h) in 55% of patients. Elevated serum cTnI and myoglobin were significantly associated with ECG signs of right ventricular strain and echocardiographic evidence of right ventricular dysfunction. Conclusion: The results of the present study demonstrate the prognostic value of cardiac specific biomarkers, cardiac troponin I & myoglobin in acute pulmonary embolism. Thus, the current data combined with the results of previous studies strongly support the integration of troponin and myoglobin testing into the risk stratification and management of patients with established acute PE.
topic Pulmonary embolism
Creatine-kinase-MB
Cardiac troponin I
Echocardiography
Cardiac biomarkers
url http://www.sciencedirect.com/science/article/pii/S0422763813002082
work_keys_str_mv AT emanoarram valueofcardiacbiomarkersinpatientswithacutepulmonaryembolism
AT amalfathy valueofcardiacbiomarkersinpatientswithacutepulmonaryembolism
AT aymanaabdelsamad valueofcardiacbiomarkersinpatientswithacutepulmonaryembolism
AT emadielmasry valueofcardiacbiomarkersinpatientswithacutepulmonaryembolism
_version_ 1725413800613511168